Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 470 Jan 1 – Oct 24, 2026
- Disclosed funding
- $19.5B 399 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| T TurbineCompany profile Virtualizes biological experiments with AI to accelerate drug discovery and clinical translation Virtualizes biological experiments with AI to accelerate drug discovery and clinical translation | $25M | Series B | Biotech | Hungary | Investors | |
| SM Slate MedicinesCompany profile Advancing next-generation therapeutics for migraine and other headache disorders Advancing next-generation therapeutics for migraine and other headache disorders | $130M | Series A | Biotech | United States | Investors | |
| V VerleyCompany profile Develops functional whey protein ingredients through precision fermentation for food and nutrition manufacturers Develops functional whey protein ingredients through precision fermentation for food and nutrition manufacturers | €32M | Series A | Biotech, Foodtech | France | Investors | |
| CT Centauri TherapeuticsCompany profile Develops immunotherapeutic treatments for antimicrobial infections Develops immunotherapeutic treatments for antimicrobial infections | £6M | Series A+Series A | Biotech | United Kingdom | Investors | |
| TT Ten63 TherapeuticsCompany profile Develops AI-driven drug discovery platform for first- and best-in-class therapeutics Develops AI-driven drug discovery platform for first- and best-in-class therapeutics | $45M | StrategicUndisclosed | Biotech, AI | United States | Investors | |
| AB Altesa BioSciencesCompany profile Clinical-stage developer of oral antiviral medicines for people with chronic lung disease. Clinical-stage developer of oral antiviral medicines for people with chronic lung disease. | $75M | Series B | Biotech | United States | Investors | |
| L LanzaJetCompany profile Develops technology for producing Sustainable Aviation Fuel (SAF) and other alternative fuels Develops technology for producing Sustainable Aviation Fuel (SAF) and other alternative fuels | $47M | Growth | Biotech, Climate tech | United States | Investors | |
| LT Lario TherapeuticsCompany profile Develops precision medicines for epileptic and neurological disorders Develops precision medicines for epileptic and neurological disorders | $2.4M | GrantUndisclosed | Biotech | United Kingdom | Investors | |
| F FlinnCompany profile Develops AI-based software to automate regulatory and quality processes in medtech and pharma Develops AI-based software to automate regulatory and quality processes in medtech and pharma | $20M | Series A | Biotech, Healthtech | Austria | Investors | |
| KB Develops therapies for neurodegenerative diseases. | $175M | Series A | Biotech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
22rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.